Current Surgical Management of Ovarian Cancer

https://doi.org/10.1016/j.hoc.2011.10.004Get rights and content

Section snippets

Surgical staging

Typically, an adnexal mass is suspected by symptom history or findings on pelvic examination. Alternatively, it may be discovered by serendipity on sonography or computed tomography (CT) scanning. Proper identification of an ovarian malignancy among patients with a pelvic mass may be aided by imaging characteristics of the mass and the rest of the abdomen, in addition to the preoperative CA125 level. More recently, the human epididymis 4 (HE4) serum marker has been approved for use in helping

Tumor debulking

Ovarian cancer is often portrayed as the disease that whispers because it does not present with dramatic bleeding, excruciating pain, or an obvious lump. Instead, the typical symptoms tend to be indolent. Patients and their health care providers often attribute such nonspecific changes to menopause, aging, dietary indiscretions, stress, depression, or functional bowel problems. Frequently, women are medically managed for indigestion or other presumed ailments without having a pelvic

Palliative surgery

Patients with relapsed ovarian cancer frequently develop bowel obstructions at some point in their treatment course. Bowel obstruction is the most common reason for hospital admission during the last year of life in patients with ovarian carcinoma.73 Often, patients can initially be managed by nasogastric suction and bowel rest. However, at some point, patients with continued progressive disease will develop worsening symptoms. If not previously addressed, such events should be incorporated

First page preview

First page preview
Click to open first page preview

References (78)

  • J.F. Magrina et al.

    Robotic approach for ovarian cancer: perioperative and survival results and comparison with laparoscopy and laparotomy

    Gynecol Oncol

    (2011)
  • O. Zivanovic et al.

    The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease

    Gynecol Oncol

    (2008)
  • S.N. Wingo et al.

    Retrospective cohort study of surgical staging for ovarian low malignant potential tumors

    Am J Obstet Gynecol

    (2006)
  • K. Houck et al.

    Borderline tumors of the ovary: correlation of frozen and permanent histopathologic diagnosis

    Obstet Gynecol

    (2000)
  • J. Brown et al.

    Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?

    Gynecol Oncol

    (2009)
  • J.M. Schilder et al.

    Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy

    Gynecol Oncol

    (2002)
  • G.G. Rao et al.

    Fertility-sparing surgery for ovarian low malignant potential tumors

    Gynecol Oncol

    (2005)
  • F. Peccatori et al.

    Surgical management of malignant ovarian germ-cell tumors: 10 years’ experience of 129 patients

    Obstet Gynecol

    (1995)
  • A.L. Covens

    A critique of surgical cytoreduction in advanced ovarian cancer

    Gynecol Oncol

    (2000)
  • G.D. Aletti et al.

    Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer

    Gynecol Oncol

    (2006)
  • E.L. Eisenhauer et al.

    The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer

    Gynecol Oncol

    (2006)
  • G.D. Aletti et al.

    Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience

    J Am Coll Surg

    (2009)
  • D.S. Chi et al.

    Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm

    Gynecol Oncol

    (2009)
  • P. Wimberger et al.

    Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

    Gynecol Oncol

    (2007)
  • D.S. Chi et al.

    What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

    Gynecol Oncol

    (2006)
  • J.A. Rauh-Hain et al.

    Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer

    Gynecol Oncol

    (2011)
  • J. Fanning et al.

    Laparoscopic-assisted cytoreduction for primary advanced ovarian cancer: success, morbidity and survival

    Gynecol Oncol

    (2011)
  • J.Y. Hou et al.

    Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease

    Gynecol Oncol

    (2007)
  • R.E. Bristow et al.

    Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis

    Gynecol Oncol

    (2006)
  • R.E. Bristow et al.

    Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction

    Gynecol Oncol

    (2007)
  • S.B. Dewdney et al.

    The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists

    Gynecol Oncol

    (2010)
  • I. Vergote et al.

    Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?

    Gynecol Oncol

    (2010)
  • R.E. Bristow et al.

    Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis

    Gynecol Oncol

    (2009)
  • R.E. Bristow et al.

    Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome

    Gynecol Oncol

    (2009)
  • S. Fotiou et al.

    Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer

    Gynecol Oncol

    (2009)
  • J.O. Schorge et al.

    Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer

    Int J Gynaecol Obstet

    (2010)
  • K.K. Shih et al.

    Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series

    Gynecol Oncol

    (2010)
  • K.K. Shih et al.

    Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

    Gynecol Oncol

    (2010)
  • V.E. von Gruenigen et al.

    Clinical disease course during the last year in ovarian cancer

    Gynecol Oncol

    (2003)
  • Cited by (46)

    • Torsion of juvenile granulosa cell ovarian tumor

      2022, Journal of Pediatric Surgery Case Reports
      Citation Excerpt :

      Fertility-sparing surgery is preferred in children, adolescents, and women when fertility preservation is desired. There is no need for hysterectomy in stage I tumors as long as the contralateral tube and ovary and the uterus are unaffected, unilateral salpingo-oophorectomy with examination of the contralateral ovary is likely sufficient [14–16]. The negative preoperative tumor markers in our patient did not rule out malignancy.

    • M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients

      2021, Gynecologic Oncology
      Citation Excerpt :

      The selection of this very high-risk population was based on achieving a relevant number of recurrences during the 18-month study follow-up period to evaluate the safety and efficacy objectives of the trial. For the stage III-IV patient population, literature shows that the median OS ranges from 24 to 50 months [3,17–21], while PFS is only 12–21 months [16–18,22]. Of the 23 subjects included, 15 patients underwent device removal due to disease progression within the 18-month study duration (65.2%), with a median PFS rate similar to that published despite including patients with a very high risk of recurrence.

    • Platinum Chemotherapy Hypersensitivity: Prevalence and Management

      2017, Immunology and Allergy Clinics of North America
      Citation Excerpt :

      As an example, it is well-described that ovarian cancer is the most fatal gynecologic malignancy.2 The standard treatment approach for newly diagnosed ovarian cancer involves multidisciplinary treatment, including surgical cytoreduction followed by a platinum-based therapy.3,4 Despite achieving initial complete clinical remission, the vast majority will go on to develop recurrent ovarian cancer.5

    View all citing articles on Scopus

    No funding disclosures.

    View full text